Cagrilintide
Cagrilintide is a long-acting amylin analogue developed by Novo Nordisk. It mimics the hormone amylin, which is co-secreted with insulin and plays a key role in satiety and gastric emptying. It is being studied in combination with Semaglutide (as CagriSema) for enhanced weight loss outcomes.
Quick facts
- Half-life
- ~7–8 days
- Administration
- Subcutaneous injection (weekly)
- Primary use
- Weight management, appetite suppression
How it works
Cagrilintide activates amylin receptors in the brain's appetite-regulating centres, slowing gastric emptying and promoting satiety independently of the GLP-1 pathway. When combined with Semaglutide, the dual mechanism produces additive appetite suppression.
Reported benefits
- Significant appetite suppression via amylin receptor activation
- Slowed gastric emptying — prolonged feeling of fullness
- Complementary mechanism to GLP-1 agonists for enhanced weight loss
- Phase 3 trials (CagriSema) showing superior weight loss to Semaglutide alone
Typical dosing protocol
Dosing
0.16–2.4 mg subcutaneously once weekly, titrated under medical supervision
Cycle length
Long-term / ongoing under medical supervision
Dosing information is for educational reference only. Individual needs vary. Always consult a healthcare professional.
Safety & considerations
Not yet approved for human use in the UK — currently in Phase 3 clinical trials. Common side effects include nausea and injection site reactions. Must only be used under medical supervision. Consult a healthcare professional before use.
Important: All content is for informational purposes only. Not medical advice. Always consult a qualified healthcare professional before starting any peptide protocol.